Authors
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Cancer Research Across Continents: Fujiwara’s Path From Japan to the USIn this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Latest:
COVID-19 and Its Impact on Oncology Clinical TrialsCoronavirus disease 2019 has disrupted oncologic care across the spectrum of cancer screening, diagnosis, and management.
Latest:
Novel Combination Therapy Impresses With Safety/Efficacy in DLBCLChristopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Latest:
Low Receipt of ACR-Recommended Follow-Care Discovered Among Patients With Lung CancerAccording to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.
Latest:
Treatment Approaches for Early-Stage Lung CancerPatrick Forde, MBBCh offers an overview of current standard-of-care treatments as well as emerging immunotherapy options for treating early-stage, resectable non-small cell lung cancer.
Latest:
Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLCJonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.
Latest:
Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium StudyResults from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
Latest:
Closing Remarks on Bispecific AntibodiesJustin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.
Latest:
Pancreatic Cancer Awareness Month: Novel Targeted Therapy in PDACThe landscape for patients with pancreatic ductal adenocarcinoma has shifted due to novel targeted therapies that are opening new options for patients.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Methods and Design of the QUILT 3032 Study in NMIBCSam S. Chang, MD, MBA, discusses the methods and design of the QUILT 3032 study.
Latest:
First- and Later-Line Therapies in Patients With GISTDomenech Asbun, MD, discusses first-, second-, and later lines of therapy for patients with gastrointestinal stromal tumor.
Latest:
Important Biomarkers for Cervical and Ovarian CancersJohn Diaz, discusses key targets for cervical cancer and ovarian cancer.
Latest:
DRd Shows Longer Time-to-Next-Treatment vs VRd in MyelomaDoris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.
Latest:
Genetic Risk Score Revolutionizes TNBC Prediction in Black WomenHolly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.
Latest:
Updated Zanidatamab Data Shows Durable Response in Biliary Tract CancerShubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.
Latest:
Exploring PSMA Therapies in Prostate CancerDeclan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
Latest:
Challenges, Unmet Needs, and the Future of Advanced Urothelial Carcinoma ManagementA key opinion leader addresses the persistent challenges and unmet needs in the management of advanced urothelial carcinoma, while offering their insight into the future direction and potential advancements within this rapidly evolving field of oncology.
Latest:
Uncovering the Mechanism of Secondary Malignancies Post-CAR TRahul Banerjee, MD, FACP, physician-researcher at Fred Hutch Cancer Center in Seattle, WA, discusses the potential links between CAR T-cell therapy and secondary T-cell malignancies.
Latest:
AI Mortality Model Predicts End of Life, Boosts Palliative CareFinly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.
Latest:
Gene Editing Used to Enhance AML Antigen Targeting for CAR T-Cell TherapySiddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.
Latest:
Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLCGiuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.
Latest:
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder CancerPetros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Latest:
Defining Advances in the WHO Classification for AMLThe required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.
Latest:
Darolutamide Plus ADT, Docetaxel Improves OS in Patients with mHSPC, Regardless of Disease Volume and RiskThe triplet therapy should become the new standard of care for this patient population, according to recent data.
Latest:
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
Latest:
Current and Emergent Therapies for Systemic MastocytosisThe field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
